

## Life Medical Sweden AB – Board of Directors

### Kjerstin Gatenbeck, President, CEO and Member of board

**Ms Kjerstin Gatenbeck** has twenty five years experience from the pharmaceutical industry, where she spent ten years with Lederle Corporation in sales and clinical research. She was as Clinical Research Manager responsible for clinical development programs in several product areas. She joined Item Development in 1994 and has since then been responsible for the product Adenosin.

Ms Gatenbeck has been responsible for Medical management of Adenosin including clinical development, registration and medical information, as well as Marketing of the product in the Nordic area.

Ms Gatenbeck holds a degree as Registered Nurse from SIHUS, the National Swedish School of Advanced Nursing Education.

### Lars Gatenbeck, Chairman

**Dr Lars Gatenbeck** is Chairman and founding partner of GZ Group, a leading Scandinavian Life Science Venture Capital Firm.

Dr Gatenbeck previously held leading positions in the European and US Pharmaceutical industry, a career including being Vice President of Pharmacia and Pharmacia Upjohn with global responsibility for several Therapy and Business Areas. Dr Gatenbeck has also been CEO and President of the Karolinska University Hospital in Stockholm, one of Europe's leading university hospitals. He has extensive experience of corporate governance as board member of several public and private companies in Europe. Public companies include Investment AB Öresund, Karo Bio, Pyrosequencing and Perbio Science.

Presently Dr Gatenbeck serves as Chairman of the board of CellaVision, and on the boards of Aerocrine AB and Aleris AB.

Dr Gatenbeck has also a number of public assignments for the Swedish Medical and Biotech community including being Chairman of Swecare and board member of Cancerföreningen and trustee of HM Gustav V anniversary fund, both cancer research foundations.

Dr Gatenbeck holds a MD and a PhD from the Karolinska Institute, Stockholm.

### Anders Wiklund, Member of board

**Mr Anders Wiklund** has been an advisor to the Biotechnology industry since 1997, when he formed Wiklund International Inc. The firm focuses on advise in the areas of Long Range Planning, mergers, partnering strategy, product acquisitions, out licensing as well as divestments/assets sales.

Mr Wiklund spent almost thirty years with the Pharmacia Group of companies in various executive positions including ten years as CEO and President of KabiVitrum Inc. and KabiPharmacia Inc. in the United States. He has also served as President of Pharmacia Development Corp., Executive Vice President of Pharmacia US Inc and Vice President of Pharmacia Upjohn.

As an advisor Mr Wiklund has worked with public and private life science companies in the USA, Canada and Scandinavia, and he was also a cofounder of Esperion Therapeutics Inc.

Presently Mr Wiklund serves on the board of QuatRx Inc, Gyros AB, InSiteVision Inc and EffRx inc.

Mr Wiklund holds a Master of Pharmacy degree from Stockholm, Sweden.